person · Reporting owner

Dier Mardi

Disclosed activity across 7 companies

Tapewire entity: 62346
SEC CIK: 0001574591

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ACELYRIN, Inc.SLRN · Entity 79310	CFO and CBO	May 09, 2023	May 11, 2023
Adamas Pharmaceuticals IncADMS · Entity 133085	Director	June 02, 2021	June 04, 2021
MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441	EVP and CFO	March 04, 2026	March 07, 2026
Oric Pharmaceuticals, Inc.ORIC · Entity 4765	Director	January 02, 2026	January 06, 2026
Prelude Therapeutics IncPRLD · Entity 5561	Director	June 12, 2025	June 13, 2025
Ultragenyx Pharmaceutical Inc.RARE · Entity 4337	CFO & Executive Vice President	October 14, 2022	October 17, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACELYRIN, Inc.

Report date May 09, 2023 · Filed May 11, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	5,556	Reported balance After 2023-05-09 transaction · row 1 1 source row Row 1 · 2023-05-09 · Purchase · Acquired 5,556 · Balance 5,556 F1: Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the "IPO").
Common StockSEC Table I · non-derivative	IndirectSee footnote	875	Reported balance After 2023-05-09 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2023-05-09 · Purchase · Acquired 875 · Balance 875 F1: Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the "IPO"). F2: The shares are held of record by one of the Reporting Person's children.
Common StockSEC Table I · non-derivative	IndirectSee footnote	875	Reported balance After 2023-05-09 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2023-05-09 · Purchase · Acquired 875 · Balance 875 F1: Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the "IPO"). F3: The shares are held of record by another one of the Reporting Person's children.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.88 · Expires 2032-11-20	Direct	0	Reported balance After 2023-05-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-05-09 · Other · Disposed 673,621 · Balance 0 F4: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F5: 1/4 of the shares subject to the option vest on November 15, 2023, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.88 · Expires 2032-11-20	Direct	673,621	Reported balance After 2023-05-09 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-05-09 · Other · Acquired 673,621 · Balance 673,621 F4: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F5: 1/4 of the shares subject to the option vest on November 15, 2023, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2033-05-03	Direct	0	Reported balance After 2023-05-09 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-05-09 · Other · Disposed 85,226 · Balance 0 F4: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2033-05-03	Direct	85,226	Reported balance After 2023-05-09 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-05-09 · Other · Acquired 85,226 · Balance 85,226 F4: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the "IPO").

F2: The shares are held of record by one of the Reporting Person's children.

F3: The shares are held of record by another one of the Reporting Person's children.

F4: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.

F5: 1/4 of the shares subject to the option vest on November 15, 2023, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.

F6: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.

Adamas Pharmaceuticals Inc

Report date June 02, 2021 · Filed June 04, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,000	Reported balance After 2021-06-02 transaction · row 1 1 source row Row 1 · 2021-06-02 · Grant · Acquired 5,000 · Balance 10,000 F1: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21 · Expires 2031-06-01	Direct	10,000	Reported balance After 2021-06-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-06-02 · Grant · Acquired 10,000 · Balance 10,000 F2: The Option shares vest in full on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.

F2: The Option shares vest in full on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date.

MADRIGAL PHARMACEUTICALS, INC.

Report date March 04, 2026 · Filed March 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	12,490	Ending reported balance After 2026-03-06 transaction · row 13 13 source rows · reconciled sequence Row 1 · 2026-03-04 · Grant · Acquired 5,215 · Balance 14,472 F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date. Row 2 · 2026-03-06 · Sale · Disposed 646 · Balance 13,826 F2: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Row 3 · 2026-03-06 · Sale · Disposed 40 · Balance 13,786 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. Row 4 · 2026-03-06 · Sale · Disposed 420 · Balance 13,366 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $426.46 to $427.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Row 5 · 2026-03-06 · Sale · Disposed 80 · Balance 13,286 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $427.50 to $428.19, inclusive. Row 6 · 2026-03-06 · Sale · Disposed 160 · Balance 13,126 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $428.51 to $429.24, inclusive. Row 7 · 2026-03-06 · Sale · Disposed 40 · Balance 13,086 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. Row 8 · 2026-03-06 · Sale · Disposed 120 · Balance 12,966 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $430.66 to $431.04, inclusive. Row 9 · 2026-03-06 · Sale · Disposed 116 · Balance 12,850 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $432.41 to $432.99, inclusive. Row 10 · 2026-03-06 · Sale · Disposed 160 · Balance 12,690 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $433.82 to $434.58, inclusive. Row 11 · 2026-03-06 · Sale · Disposed 80 · Balance 12,610 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $435.26 to $435.37, inclusive. Row 12 · 2026-03-06 · Sale · Disposed 80 · Balance 12,530 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $436.46 to $436.92, inclusive. Row 13 · 2026-03-06 · Sale · Disposed 40 · Balance 12,490 F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $434.80 · Expires 2036-03-04	Direct	6,519	Reported balance After 2026-03-04 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2026-03-04 · Grant · Acquired 6,519 · Balance 6,519 F12: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date.

F2: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

F3: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $426.46 to $427.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $427.50 to $428.19, inclusive.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $428.51 to $429.24, inclusive.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $430.66 to $431.04, inclusive.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $432.41 to $432.99, inclusive.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $433.82 to $434.58, inclusive.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $435.26 to $435.37, inclusive.

F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $436.46 to $436.92, inclusive.

F12: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

Oric Pharmaceuticals, Inc.

Report date January 02, 2026 · Filed January 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.17 · Expires 2036-01-01	Direct	40,000	Reported balance After 2026-01-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-02 · Grant · Acquired 40,000 · Balance 40,000 F1: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.

Prelude Therapeutics Inc

Report date June 12, 2025 · Filed June 13, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.04 · Expires 2035-06-11	Direct	38,000	Reported balance After 2025-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-06-12 · Grant · Acquired 38,000 · Balance 38,000 F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.

Ultragenyx Pharmaceutical Inc.

Report date October 14, 2022 · Filed October 17, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	66,695	Reported balance After 2022-10-14 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2022-10-14 · Sale · Disposed 1,629 · Balance 66,695 F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

PORTOLA PHARMACEUTICALS INC

Report date July 02, 2020 · Filed July 02, 2020

Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2020-07-02 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2020-07-02 · Disposition to issuer · Disposed 39,563 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.
Common StockSEC Table I · non-derivative	Direct	10	Reported balance After 2020-06-18 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2020-06-18 · Grant · Acquired 10 · Balance 10 F2: The acquisition of 10 shares by the Reporting Person on June 18, 2020 pursuant to the Issuer's Employee Stock Purchase Plan.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2020-07-02 transaction · row 3 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 3 · 2020-07-02 · Disposition to issuer · Disposed 10 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-07-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-07-02 · Disposition to issuer · Disposed 48,750 · Balance 0 F3: Immediately prior to the Effective Time, each performance restricted stock unit ( "Issuer PSU") was converted into a restricted stock unit with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer PSU by (ii) an exchange ratio equal to $18.00 divided by $112.39 (the "Exchange Ratio").
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-07-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-07-02 · Disposition to issuer · Disposed 24,375 · Balance 0 F4: In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.79 · Expires 2030-01-30	Direct	0	Reported balance After 2020-07-02 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-07-02 · Disposition to issuer · Disposed 65,000 · Balance 0 F5: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.79 · Expires 2030-01-30	Direct	0	Reported balance After 2020-07-02 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-07-02 · Disposition to issuer · Disposed 32,500 · Balance 0 F6: At the Effective Time, each of these unvested and outstanding options became fully vested (assuming performance at target), canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that were subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-07-02 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-07-02 · Disposition to issuer · Disposed 371,545 · Balance 0 F7: In connection with the Merger, these options were accelerated and canceled without payment.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-07-02 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-07-02 · Disposition to issuer · Disposed 32,291 · Balance 0 F8: At the Effective Time, each restricted stock unit ("Issuer RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.

F2: The acquisition of 10 shares by the Reporting Person on June 18, 2020 pursuant to the Issuer's Employee Stock Purchase Plan.

F3: Immediately prior to the Effective Time, each performance restricted stock unit ( "Issuer PSU") was converted into a restricted stock unit with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer PSU by (ii) an exchange ratio equal to $18.00 divided by $112.39 (the "Exchange Ratio").

F4: In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time.

F5: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.

F6: At the Effective Time, each of these unvested and outstanding options became fully vested (assuming performance at target), canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that were subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.

F7: In connection with the Merger, these options were accelerated and canceled without payment.

F8: At the Effective Time, each restricted stock unit ("Issuer RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 06, 2026 Filed Mar 7, 2026 00:18 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	40	$437.65	$17,506.00	Disclosure SEC source: 0001628280-26-015775 · wk-form4_1772842708.xml · nonDerivative · entry 13 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,490 F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. Read SEC document
March 06, 2026 Filed Mar 7, 2026 00:18 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	80	$436.69	$34,935.20	Disclosure SEC source: 0001628280-26-015775 · wk-form4_1772842708.xml · nonDerivative · entry 12 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,530 F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $436.46 to $436.92, inclusive. Read SEC document
March 06, 2026 Filed Mar 7, 2026 00:18 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	80	$435.32	$34,825.20	Disclosure SEC source: 0001628280-26-015775 · wk-form4_1772842708.xml · nonDerivative · entry 11 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,610 F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $435.26 to $435.37, inclusive. Read SEC document
March 06, 2026 Filed Mar 7, 2026 00:18 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	160	$434.20	$69,472.00	Disclosure SEC source: 0001628280-26-015775 · wk-form4_1772842708.xml · nonDerivative · entry 10 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,690 F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $433.82 to $434.58, inclusive. Read SEC document
March 06, 2026 Filed Mar 7, 2026 00:18 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	116	$432.56	$50,176.48	Disclosure SEC source: 0001628280-26-015775 · wk-form4_1772842708.xml · nonDerivative · entry 9 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,850 F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $432.41 to $432.99, inclusive. Read SEC document
March 06, 2026 Filed Mar 7, 2026 00:18 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	120	$430.90	$51,708.40	Disclosure SEC source: 0001628280-26-015775 · wk-form4_1772842708.xml · nonDerivative · entry 8 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,966 F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $430.66 to $431.04, inclusive. Read SEC document
March 06, 2026 Filed Mar 7, 2026 00:18 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	40	$429.58	$17,183.20	Disclosure SEC source: 0001628280-26-015775 · wk-form4_1772842708.xml · nonDerivative · entry 7 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,086 F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. Read SEC document
March 06, 2026 Filed Mar 7, 2026 00:18 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	160	$429.00	$68,639.20	Disclosure SEC source: 0001628280-26-015775 · wk-form4_1772842708.xml · nonDerivative · entry 6 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,126 F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $428.51 to $429.24, inclusive. Read SEC document
March 06, 2026 Filed Mar 7, 2026 00:18 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	80	$427.85	$34,227.60	Disclosure SEC source: 0001628280-26-015775 · wk-form4_1772842708.xml · nonDerivative · entry 5 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,286 F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $427.50 to $428.19, inclusive. Read SEC document
March 06, 2026 Filed Mar 7, 2026 00:18 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	420	$426.86	$179,282.80	Disclosure SEC source: 0001628280-26-015775 · wk-form4_1772842708.xml · nonDerivative · entry 4 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,366 F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $426.46 to $427.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document
March 06, 2026 Filed Mar 7, 2026 00:18 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	40	$425.08	$17,003.20	Disclosure SEC source: 0001628280-26-015775 · wk-form4_1772842708.xml · nonDerivative · entry 3 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,786 F3 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. Read SEC document
March 06, 2026 Filed Mar 7, 2026 00:18 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	646	$431.94	$279,033.24	Disclosure SEC source: 0001628280-26-015775 · wk-form4_1772842708.xml · nonDerivative · entry 2 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,826 F2 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document
March 04, 2026 Filed Mar 7, 2026 00:18 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	GrantStock Option (Right to Buy) · Derivative	6,519	$0.00 Strike: $434.80	$0.00	Disclosure SEC source: 0001628280-26-015775 · wk-form4_1772842708.xml · derivative · entry 14 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,519 Underlying: Common Stock · 6,519 shares Expires 2036-03-04 F12 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document
March 04, 2026 Filed Mar 7, 2026 00:18 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	GrantCommon Stock	5,215	$0.00	$0.00	Disclosure SEC source: 0001628280-26-015775 · wk-form4_1772842708.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,472 F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document
March 02, 2026 Filed Mar 2, 2026 22:32 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	1,183	$427.21	$505,389.43	Disclosure SEC source: 0001628280-26-013394 · wk-form4_1772490753.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,257 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document
January 02, 2026 Filed Jan 6, 2026 16:44 UTC	Oric Pharmaceuticals, Inc. ORIC · Entity 4765	GrantStock Option (right to buy) · Derivative	40,000	$0.00 Strike: $8.17	$0.00	Disclosure SEC source: 0001574591-26-000002 · form4-01062026_090138.xml · derivative · entry 1 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026. Read SEC document
December 02, 2025 Filed Dec 3, 2025 22:59 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	Exercise / conversionStock Option (Right to Buy) · Derivative	4,173	$0.00 Strike: $251.63	$0.00	Disclosure SEC source: 0001628280-25-055164 · wk-form4_1764802770.xml · derivative · entry 17 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,180 Underlying: Common Stock · 4,173 shares Expires 2034-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F17 · derivative.exercise_date: All shares issued pursuant to the exercise of the options reported herein represent 4,173 shares underlying an overall option award of 13,353 shares. All exercised options had vested. As to the overall option for 13,353 shares, 25% of the shares vested on March 1, 2025, and, thereafter, 6.25% of the shares vested or will vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document
December 02, 2025 Filed Dec 3, 2025 22:59 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	80	$596.19	$47,694.80	Disclosure SEC source: 0001628280-25-055164 · wk-form4_1764802770.xml · nonDerivative · entry 16 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,440 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $596.18 to $596.19, inclusive. Read SEC document
December 02, 2025 Filed Dec 3, 2025 22:59 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	74	$595.20	$44,045.15	Disclosure SEC source: 0001628280-25-055164 · wk-form4_1764802770.xml · nonDerivative · entry 15 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,520 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $595.18 to $595.41, inclusive. Read SEC document
December 02, 2025 Filed Dec 3, 2025 22:59 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	160	$590.37	$94,459.60	Disclosure SEC source: 0001628280-25-055164 · wk-form4_1764802770.xml · nonDerivative · entry 14 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,594 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.15 to $590.58, inclusive. Read SEC document
December 02, 2025 Filed Dec 3, 2025 22:59 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	160	$589.65	$94,343.66	Disclosure SEC source: 0001628280-25-055164 · wk-form4_1764802770.xml · nonDerivative · entry 13 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,754 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.13 to $589.96, inclusive. Read SEC document
December 02, 2025 Filed Dec 3, 2025 22:59 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	240	$587.85	$141,083.88	Disclosure SEC source: 0001628280-25-055164 · wk-form4_1764802770.xml · nonDerivative · entry 12 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,914 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.58 to $588.07, inclusive. Read SEC document
December 02, 2025 Filed Dec 3, 2025 22:59 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	240	$585.44	$140,505.19	Disclosure SEC source: 0001628280-25-055164 · wk-form4_1764802770.xml · nonDerivative · entry 11 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,154 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.08 to $585.99, inclusive. Read SEC document
December 02, 2025 Filed Dec 3, 2025 22:59 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	480	$579.85	$278,329.20	Disclosure SEC source: 0001628280-25-055164 · wk-form4_1764802770.xml · nonDerivative · entry 10 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,394 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.59 to $580.46, inclusive. Read SEC document
December 02, 2025 Filed Dec 3, 2025 22:59 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	258	$578.83	$149,338.40	Disclosure SEC source: 0001628280-25-055164 · wk-form4_1764802770.xml · nonDerivative · entry 9 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,874 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $578.37 to $579.20, inclusive. Read SEC document
December 02, 2025 Filed Dec 3, 2025 22:59 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	320	$577.81	$184,900.61	Disclosure SEC source: 0001628280-25-055164 · wk-form4_1764802770.xml · nonDerivative · entry 8 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,132 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.36 to $578.31, inclusive. Read SEC document
December 02, 2025 Filed Dec 3, 2025 22:59 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	240	$576.15	$138,276.41	Disclosure SEC source: 0001628280-25-055164 · wk-form4_1764802770.xml · nonDerivative · entry 7 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,452 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.69 to $576.46, inclusive. Read SEC document
December 02, 2025 Filed Dec 3, 2025 22:59 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	120	$574.95	$68,994.29	Disclosure SEC source: 0001628280-25-055164 · wk-form4_1764802770.xml · nonDerivative · entry 6 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,692 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.67 to $575.24, inclusive. Read SEC document
December 02, 2025 Filed Dec 3, 2025 22:59 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	717	$574.00	$411,558.79	Disclosure SEC source: 0001628280-25-055164 · wk-form4_1764802770.xml · nonDerivative · entry 5 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,812 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.59 to $574.44, inclusive. Read SEC document
December 02, 2025 Filed Dec 3, 2025 22:59 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	354	$573.02	$202,847.35	Disclosure SEC source: 0001628280-25-055164 · wk-form4_1764802770.xml · nonDerivative · entry 4 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,529 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.48 to $573.38, inclusive. Read SEC document
December 02, 2025 Filed Dec 3, 2025 22:59 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	410	$571.99	$234,515.57	Disclosure SEC source: 0001628280-25-055164 · wk-form4_1764802770.xml · nonDerivative · entry 3 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,883 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.45 to $572.34, inclusive. Read SEC document
December 02, 2025 Filed Dec 3, 2025 22:59 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	320	$570.39	$182,523.52	Disclosure SEC source: 0001628280-25-055164 · wk-form4_1764802770.xml · nonDerivative · entry 2 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,293 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $570.17 to $570.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document
December 02, 2025 Filed Dec 3, 2025 22:59 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	Exercise / conversionCommon Stock	4,173	$251.63	$1,050,051.99	Disclosure SEC source: 0001628280-25-055164 · wk-form4_1764802770.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 12, 2025 Filed Jun 13, 2025 16:15 UTC	Prelude Therapeutics Inc PRLD · Entity 5561	GrantDirector Stock Option (Right to Buy) · Derivative	38,000	$0.00 Strike: $1.04	$0.00	Disclosure SEC source: 0001562180-25-004797 · primarydocument.xml · derivative · entry 1 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
March 10, 2025 Filed Mar 12, 2025 20:32 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	258	$323.04	$83,344.32	Disclosure SEC source: 0001628280-25-012369 · wk-form4_1741811523.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · SVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,440 F1 · kind: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2024. Read SEC document
March 05, 2025 Filed Mar 7, 2025 22:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	GrantStock Option (Right to Buy) · Derivative	6,374	$0.00 Strike: $347.28	$0.00	Disclosure SEC source: 0001628280-25-011407 · wk-form4_1741387433.xml · derivative · entry 2 Dier Mardi · CIK 0001574591 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,374 Underlying: Common Stock · 6,374 shares Expires 2035-03-05 F2 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2026) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document
March 05, 2025 Filed Mar 7, 2025 22:43 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	GrantCommon Stock	3,784	$0.00	$0.00	Disclosure SEC source: 0001628280-25-011407 · wk-form4_1741387433.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · SVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,698 F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:31 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	774	$323.54	$250,416.63	Disclosure SEC source: 0001628280-25-010508 · wk-form4_1741210303.xml · nonDerivative · entry 2 Dier Mardi · CIK 0001574591 · SVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,914 F2 · kind: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.38 to $323.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
March 03, 2025 Filed Mar 5, 2025 21:31 UTC	MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441	SaleCommon Stock	1,187	$325.89	$386,831.43	Disclosure SEC source: 0001628280-25-010508 · wk-form4_1741210303.xml · nonDerivative · entry 1 Dier Mardi · CIK 0001574591 · SVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,688 F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person. Read SEC document
January 02, 2025 Filed Jan 6, 2025 16:43 UTC	Oric Pharmaceuticals, Inc. ORIC · Entity 4765	GrantStock Option (right to buy) · Derivative	35,000	$0.00 Strike: $8.26	$0.00	Disclosure SEC source: 0001415889-25-000782 · form4-01062025_090133.xml · derivative · entry 1 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-01-01 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2025. Read SEC document
June 14, 2024 Filed Jun 18, 2024 16:13 UTC	Prelude Therapeutics Inc PRLD · Entity 5561	GrantDirector Stock Option (Right to Buy) · Derivative	23,500	$0.00 Strike: $3.90	$0.00	Disclosure SEC source: 0001562180-24-005161 · primarydocument.xml · derivative · entry 1 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2034-06-13 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
June 12, 2024 Filed Jun 14, 2024 16:22 UTC	Oric Pharmaceuticals, Inc. ORIC · Entity 4765	GrantStock Option (right to buy) · Derivative	25,600	$0.00 Strike: $7.90	$0.00	Disclosure SEC source: 0001415889-24-016906 · form4-06142024_080637.xml · derivative · entry 1 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,600 Underlying: Common Stock · 25,600 shares Expires 2034-06-11 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 12, 2025 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document
June 16, 2023 Filed Jun 21, 2023 16:13 UTC	Prelude Therapeutics Inc PRLD · Entity 5561	GrantDirector Stock Option (Right to Buy) · Derivative	23,500	$0.00 Strike: $5.56	$0.00	Disclosure SEC source: 0001209191-23-038773 · doc4.xml · derivative · entry 1 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2033-06-15 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
June 14, 2023 Filed Jun 15, 2023 16:52 UTC	Oric Pharmaceuticals, Inc. ORIC · Entity 4765	GrantStock Option (right to buy) · Derivative	20,500	$0.00 Strike: $6.33	$0.00	Disclosure SEC source: 0001209191-23-037393 · doc4.xml · derivative · entry 1 Dier Mardi · CIK 0001574591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 20,500 shares Expires 2033-06-13 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 14, 2024 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document
May 09, 2023 Filed May 11, 2023 20:51 UTC	ACELYRIN, Inc. SLRN · Entity 79310	OtherEmployee Stock Option (right to buy) · Derivative	85,226	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0001209191-23-028864 · doc4.xml · derivative · entry 7 Dier Mardi · CIK 0001574591 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,226 Underlying: Common Stock · 85,226 shares Expires 2033-05-03 F4 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6 · derivative.exercise_date: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F4 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Read SEC document
May 09, 2023 Filed May 11, 2023 20:51 UTC	ACELYRIN, Inc. SLRN · Entity 79310	OtherEmployee Stock Option (right to buy) · Derivative	85,226	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0001209191-23-028864 · doc4.xml · derivative · entry 6 Dier Mardi · CIK 0001574591 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 85,226 shares Expires 2033-05-03 F4 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F6 · derivative.exercise_date: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F4 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Read SEC document
May 09, 2023 Filed May 11, 2023 20:51 UTC	ACELYRIN, Inc. SLRN · Entity 79310	OtherEmployee Stock Option (right to buy) · Derivative	673,621	$0.00 Strike: $5.88	$0.00	Disclosure SEC source: 0001209191-23-028864 · doc4.xml · derivative · entry 5 Dier Mardi · CIK 0001574591 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 673,621 Underlying: Common Stock · 673,621 shares Expires 2032-11-20 F4 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vest on November 15, 2023, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. F4 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Read SEC document
May 09, 2023 Filed May 11, 2023 20:51 UTC	ACELYRIN, Inc. SLRN · Entity 79310	OtherEmployee Stock Option (right to buy) · Derivative	673,621	$0.00 Strike: $5.88	$0.00	Disclosure SEC source: 0001209191-23-028864 · doc4.xml · derivative · entry 4 Dier Mardi · CIK 0001574591 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 673,621 shares Expires 2032-11-20 F4 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vest on November 15, 2023, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. F4 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Read SEC document
May 09, 2023 Filed May 11, 2023 20:51 UTC	ACELYRIN, Inc. SLRN · Entity 79310	PurchaseCommon Stock	875	$18.00	$15,750.00	Disclosure SEC source: 0001209191-23-028864 · doc4.xml · nonDerivative · entry 3 Dier Mardi · CIK 0001574591 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 875 F1 · shares: Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the "IPO"). F3 · ownership.nature: The shares are held of record by another one of the Reporting Person's children. Read SEC document
May 09, 2023 Filed May 11, 2023 20:51 UTC	ACELYRIN, Inc. SLRN · Entity 79310	PurchaseCommon Stock	875	$18.00	$15,750.00	Disclosure SEC source: 0001209191-23-028864 · doc4.xml · nonDerivative · entry 2 Dier Mardi · CIK 0001574591 · CFO and CBO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 875 F1 · shares: Reflects shares purchased through a directed share program in the Issuer's initial public offering of Common Stock (the "IPO"). F2 · ownership.nature: The shares are held of record by one of the Reporting Person's children. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.